PI3Kδ inhibitor
Leniolisib
Brand names: Joenja
Adult dose
Dose: 70mg PO BD with food (≥12y, ≥45kg)
Route: PO
Frequency: BD
Clinical pearls
- Activated PI3Kδ syndrome (APDS) — specialist immunology
Contraindications
- Pregnancy/breastfeeding
- Severe hepatic impairment
Side effects
- Diarrhoea
- Sinusitis
- Headache
- Atopic dermatitis
- Pyrexia
Interactions
- Strong CYP3A4 modulators
- P-gp substrates
Monitoring
- FBC
- LFTs
Reference: BNF; SmPC; https://bnf.nice.org.uk/drugs/leniolisib/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022